• Global Market
  • China Market
  •  

    Global Market

    With China's rapid economic development, Techdow has been constantly improving the management capacity and production capacity in more than ten years –development to accomplish internationalized layout. Techdow has marketed in more than 20 countries for more than 10 years. Techdow ‘s export quantity & value accounted for nearly 50% of all the China LWMHs exporting, ranking No.1 nationwide.

    Techdow has attributed its product in these countries as below: United States, Poland, Russia, Germany, Italy, Australia, South Korea, Thailand, Vietnam, Iran, India, Bangladesh, the Philippines, Malaysia, Singapore, Indonesia, Pakistan and so on. Based on the superior R&D strength, strong production capacity, high-quality product strength, and extensive marketing network, Techdow will develop more rapidly in the international market in the future.

     

  • 深圳市天道医药有限公司作为国内的一家工艺技术领先的专业制药企业,专注于依诺肝素钠原料药及其制剂产品的研发和销售,并凭借独特的产品竞争力和健全的销售网络,市场份额和品牌在国内市场上稳健提升。随着近年来国家和政府大力推行的医药改革,致力于为所有公民提供基本医疗服务,并逐步缩小城乡居民在获得医疗资源方面的巨大差异,同时,依诺肝素钠制剂在2015年已被纳入国家医保目录,天道医药普洛静必将为患者带来更多的福音,为政府分忧,为客户提供更多的附加值。

    随着人口老龄化加剧和生活方式的改变,心血管发病率逐年增加,国内低分子肝素市场用药潜力巨大,驱动抗凝治疗市场销售份额稳健增长,且随着国家对“低分子肝素”药品分类、质量标准提高工作及仿制药质量和疗效一致性评价等的进行,国内市场上达不到分类要求的“低分子肝素”药品将被迫升级或被依诺肝素等替代,这也是天道医药进一步拓展国内市场的一大契机。

    公司目前已在上海、浙江、河北、湖北、四川等省市展开销售,市场口碑极佳。随着其他省市陆续中标挂网,天道医药普洛静的市场份额将进一步扩大,天道医药作为国内依诺肝素首仿企业,具备国际一流的高品质,必将成为依诺肝素国内市场的领头羊。